Colchicine and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis of Randomized Controlled Trials

被引：0

作者：

Wang, Michael K. ^{[1
,2
]}

Razeghi, Ghazal ^{[3
]}

Eikelboom, John W. ^{[1
,2
]}

Devereaux, P. J. ^{[1
,2
,4
]}

Budgeon, Charley A. ^{[3
,5
]}

Jacka, Michael J. ^{[6
]}

Wright, David J. ^{[7
]}

Latini, Roberto ^{[8
]}

Conen, David ^{[1
,2
,4
]}

机构：

[1] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada

[2] McMaster Univ, Dept Med, Hamilton, ON, Canada

[3] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada

[4] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada

[5] Univ Western Australia, Sch Populat & Global Hlth, Perth, Australia

[6] Univ Alberta, Edmonton, AB, Canada

[7] Liverpool Heart & Chest Hosp, Liverpool, England

[8] Mario Negri Inst Pharmacol Res IRCCS, Dept Cardiovasc Res, Milan, Italy

来源：

CANADIAN JOURNAL OF CARDIOLOGY | 2024年 / 40卷 / 07期

关键词：

D O I：

10.1016/j.cjca.2023.12.036

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Colchicine is an inexpensive anti-inflammatory drug used for treating gout and pericarditis. Two large randomized controlled trials (RCTs) showed that colchicine prevents adverse cardiovascular outcomes such as myocardial infarction, stroke, and cardiovascular death in patients with coronary artery disease.1,2 Some trials have suggested that there might be a greater risk of venous thromboembolism (VTE) systematic review and meta-analysis of RCTs to determine the effect of colchicine on the risk of VTE.

引用

页码：1344 / 1346

页数：3

共 50 条

[31] Systematic Review, Meta-Analysis and Randomized Controlled Trials in Cytopathology
AbdullGaffar, Badr
ACTA CYTOLOGICA, 2012, 56 (03) : 221 - 227
[32] injury: A systematic review and meta-analysis of randomized controlled trials
Daou, Marietou
Dionne, Joanna C.
Teng, Jennifer F. T.
Taran, Shaurya
Zytaruk, Nicole
Cook, Deborah
Wilcox, M. Elizabeth
JOURNAL OF CRITICAL CARE, 2022, 71
[33] Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials
Rosenberg, D.
Avni, T.
Tsvetov, G.
Gafter-Gvili, A.
Diker-Cohen, T.
OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 413 - 424
[34] Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials
Rosenberg, D.
Avni, T.
Tsvetov, G.
Gafter-Gvili, A.
Diker-Cohen, T.
OSTEOPOROSIS INTERNATIONAL, 2021, 32 (10) : 2131 - 2131
[35] Risk of Venous Thromboembolic Events in Patients With Cancer Treated With Aflibercept: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Kanukula, Raju
Ganta, Shruthi
Sirumalla, Yashaswee
Salam, Abdul
Baddam, Ravali
Pasupuleti, Bhuvana C.
AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (04) : E549 - E552
[36] Therapeutic Hypothermia and the Risk of Hemorrhage A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Wang, Chih-Hung
Chen, Nai-Chuan
Tsai, Min-Shan
Yu, Ping-Hsun
Wang, An-Yi
Chang, Wei-Tien
Huang, Chien-Hua
Chen, Wen-Jone
MEDICINE, 2015, 94 (47) : e2152
[37] Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials
D. Rosenberg
T. Avni
G. Tsvetov
A. Gafter-Gvili
T. Diker-Cohen
Osteoporosis International, 2021, 32 : 413 - 424
[38] Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials
D. Rosenberg
T. Avni
G. Tsvetov
A. Gafter-Gvili
T. Diker-Cohen
Osteoporosis International, 2021, 32 : 2131 - 2131
[39] MAJOR ADVERSE CARDIAC EVENTS AND VENOUS THROMBOEMBOLISM RISK WITH JAK INHIBITORS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Maqsood, Muhammad Haisum
Ottensoser, Molly
Berger, Jeffrey S.
Bangalore, Sripal
Garshick, Michael Seth
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1796 - 1796
[40] Venous thromboembolism and race: A systematic review and meta-analysis
Butterworth, K.
Iyen, B.
Grainge, M. J.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 137 - 138

← 1 2 3 4 5 →